Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage

Study acronym: CAPTAIN
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Beijing Tiantan Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 8 more changesShow less
    • Recruitment opened
    • Enrollment increased: 316 → 380 participants
    • Start date changed from estimate of Nov 30, 2025 to Dec 6, 2025
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: 3 to 5
    • Study description expanded, about 7 words
    • Site details revised
    • Publications: details revised at 24 of 24 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The investigators propose to conduct a multicenter randomized trial to test whether cilostazol reduces the incidence of delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) and improves patients' neurological prognosis, while assessing its safety.
Trial Details
NCT Number NCT07249853
Lead Sponsor Beijing Tiantan Hospital
Conditions
(from sponsor)		 Aneurysmal Subarachnoid Hemorrhage
Related terms Subarachnoid Hemorrhage
Enrollment 380 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov